ATC Group: N05AX Other antipsychotics

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Nervous system
2
Psycholeptics
3
Antipsychotics
4
N05AX
Other antipsychotics

ATC group contents

Code
Title
Prothipendyl
Risperidone
Mosapramine
Zotepine
Aripiprazole
Paliperidone
Iloperidone
Cariprazine
Brexpiprazole
Pimavanserin

Active ingredients

Active Ingredient
Description

It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.

Brexpiprazole is an atypical antipsychotic agent. The pharmacology of brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors.

Cariprazine is indicated for the treatment of schizophrenia in adult patients. The mechanism of action of cariprazine is not fully known. However the therapeutic effect of cariprazine may be mediated through a combination of partial agonist activity at dopamine D3, D2 (Ki values of 0.085-0.3 nM versus 0.49-0.71 nM respectively) and serotonin 5-HT1A receptors (Ki values of 1.4-2.6 nM), and antagonist activity at serotonin 5-HT2B, 5-HT2A and histamine H1 receptors (Ki values of 0.58-1.1 nM, 18.8 nM and 23.3 nM, respectively).

Iloperidone is a psychotropic agent used for the treatment of adults with schizophrenia. It is proposed that the efficacy of iloperidone is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonisms.

Paliperidone is a selective blocking agent of monoamine effects, whose pharmacological properties are different from that of traditional neuroleptics. Even though paliperidone is a strong D2-antagonist, which is believed to relieve the positive symptoms of schizophrenia, it causes less catalepsy and decreases motor functions to a lesser extent than traditional neuroleptics.

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The mechanism of action of is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.

Risperidone is a selective monoaminergic antagonist with unique properties. Although risperidone is a potent D2 antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics.

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
Structured Product Labeling (SPL/PLR)
US
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
IE
Summary of Product Characteristics (SPC)
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
Medication Package Insert (MPI)
SG
Summary of Product Characteristics (SPC)